How much is a cldx stock worth?
One share of CLDX stock can currently be purchased for approximately $27.87. How much money does Celldex Therapeutics make? Celldex Therapeutics has a market capitalization of $1.30 billion and generates $7.42 million in revenue each year.
What is the current price of Celldex Therapeutics stock?
Since then, CLDX shares have increased by 1,272.9% and is now trading at $27.87. View which stocks have been most impacted by COVID-19. When is Celldex Therapeutics' next earnings date? Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
What does cldx stand for?
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
How much money does Celldex make a year?
Celldex Therapeutics has a market capitalization of $1.30 billion and generates $7.42 million in revenue each year. The biopharmaceutical company earns $-59.78 million in net income (profit) each year or ($1.76) on an earnings per share basis. How many employees does Celldex Therapeutics have?
Is Cldx a buy now?
Celldex Therapeutics Inc (NASDAQ:CLDX) The 6 analysts offering 12-month price forecasts for Celldex Therapeutics Inc have a median target of 68.00, with a high estimate of 73.00 and a low estimate of 59.00. The median estimate represents a +177.89% increase from the last price of 24.47.
What does Celldex Therapeutics do?
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.
When was celldex founded?
Celldex Therapeutics Inc (NASDAQ:CLDX) Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
What does relay therapeutics do?
Relay Therapeutics® is creating new possibilities in drug discovery. We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease.
Should I buy or sell Celldex Therapeutics stock right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are current...
What is Celldex Therapeutics' stock price forecast for 2022?
5 Wall Street research analysts have issued 1-year price targets for Celldex Therapeutics' stock. Their CLDX stock forecasts range from $60.00 to $...
How has Celldex Therapeutics' stock performed in 2022?
Celldex Therapeutics' stock was trading at $38.64 at the beginning of 2022. Since then, CLDX stock has decreased by 43.9% and is now trading at $21...
When is Celldex Therapeutics' next earnings date?
Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.49)...
When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?
Celldex Therapeutics shares reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8t...
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the following people: Mr. Anthony S. Marucci M.B.A. , Founder, Pres, CEO & Director (Age 60, Pay...
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regener...
What other stocks do shareholders of Celldex Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OP...
Signals & Forecast
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 13.75%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices.
Is Celldex Therapeutics stock A Buy?
Celldex Therapeutics finds support from accumulated volume at $31.06 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Celldex Therapeutics
Celldex Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Celldex Therapeutics
In the last 100 trades there were 2.14 million shares bought and 163.34 thousand shares sold. The last trade was done 48 days ago by Martin Samuel Bates who sold 3.75 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is CDX-0159?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
When is Motley Fool Live 2021?
The company is evaluating CDX-0159 in two ongoing Phase 1b trials in patients with chronic spontaneous urticaria and chronic inducible urticaria. Hives (urticaria) are red, itchy welts that result from a skin reaction. In December last year, the company dosed the first patient in a chronic inducible urticaria study. Initial data is expected at the end of the first quarter of 2021. A chronic spontaneous urticaria study was initiated in October last year, with results expected in the second half of 2021. CDX-0159 is a humanized monoclonal antibody that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in various cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. Price Action: CLDX closed 1.3% higher at $28.25 on Monday. See more from BenzingaClick here for options trades from BenzingaRevance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb SpasticityCompugen To Test COM701, Opdivo Combination In Solid Tumor Settings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.